Monitor SONATA-HCM top-line results in Q1 2027 and the ZYNQUISTA NDA resubmission timeline; the cash runway of $183M supports operations into 2027 without near-term financing.
Drugs in focus
LXRX drug pipeline →ZYNQUISTA
◆ Mixed Named in this 8-K- Impact
- Phase
- Filed/Pre-NDA resubmission (already approved as Inpefa for heart failure)
- Time to market
- Uncertain. NDA resubmission expected Q4 2026; if accepted, FDA has up to 6 months to review a Class 2 resubmission, meaning a potential decision in mid-2027 at the earliest.
- Next catalyst
- None dated
What to watchWatch for Zynquista NDA resubmission announcement in Q4 2026, that event will signal whether Lexicon believes it has adequately addressed FDA concerns. Success would be a major de-risking event; failure or further delay would be a severe blow given the company's pipeline reliance on sotagliflozin. The ~41.6% implied upside to the analyst mean price target reflects the binary nature of this catalyst.
Price Chart
Executive Summary
Lexicon reported Q3 2026 total revenue of $11.3M, down from $14.2M a year ago, driven by lower licensing/milestone revenue ($10.0M vs $13.2M). Net loss widened to $14.0M ($0.03 per share) from $12.8M ($0.04 per share). The company highlighted completion of SONATA-HCM enrollment (542 patients) and positive STENO1 safety data supporting a planned ZYNQUISTA NDA resubmission in Q1 2027.
Key Financial Metrics
Key Facts
- Total revenue $11.3M vs $14.2M in Q3 2025, a 20.6% decline
- Net loss $14.0M ($0.03 per share) vs $12.8M ($0.04 per share) in Q3 2025
- Cash and investments $183.2M as of Sep 30, 2026, down from $190.6M at Jun 30, 2026
- SONATA-HCM Phase 3 study enrolled 542 patients, top-line data expected Q1 2027
- STENO1 safety data achieved FDA requirements for ZYNQUISTA NDA resubmission, planned Q1 2027
- Earned third $10M milestone from Novo for LX9851 in August 2026, total $75M earned to date
- FDA raised no objections to advancing pilavapadin into Phase 3 development
Financial Impact
Revenue decline of $2.9M YoY; net loss increased by $1.2M; cash burn of $7.4M in Q3
Risk Factors
- Revenue decline driven by lower milestone payments from Novo, which are lumpy and non-recurring
- Net loss continues to widen as R&D and SG&A expenses remain elevated
- Clinical trial risks for SONATA-HCM and ZYNQUISTA NDA resubmission
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001062822-26-000124 |
| Document: lxrx-20261105.htm | 0001062822-26-000124 |
| Document: 0001062822-26-000124-index-headers.html | 0001062822-26-000124 |
| Document: 0001062822-26-000124-index.html | 0001062822-26-000124 |
| Document: 0001062822-26-000124.txt | 0001062822-26-000124 |
| 8-K Data (Synthetic) | 0001062822-26-000124 |
Track record
16 reports on LXRX
4 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +27.52% at T+20 after the Sep 22, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Viewing No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
- Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $2.18 to $2.06 Now $1.75 +19.72% ▲ +5.50% +4.78% vs SPY
- Aug 6, 202614w ago 8-K Neutral 5/10 No price data
- Aug 6, 202614w ago Press Release Neutral 5/10 Entry $2.36 to $2.47 Now $1.75 −25.85% ▲ +4.66% +4.05% vs SPY
- Jun 12, 202622w ago Institutional Cluster Bearish 5/10 Entry $1.92 to $1.96 Now $1.75 +8.85% ▼ −2.08% −0.32% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.89 to $1.92 Now $1.75 −7.41% ▲ +1.59% +1.05% vs SPY
- May 6, 202627w ago 8-K Neutral 4/10 Entry $1.68 to $1.68 Now $1.75 +4.17% · 0.00% −0.83% vs SPY
- Apr 30, 202628w ago 8-K Bearish 6/10 Entry $1.63 to $1.60 Now $1.75 −7.36% ▲ +1.84% +1.50% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers